Menogaril-resistant P388 leukemia cells and their resistance mechanisms
Author Information
Author(s): G.J. Badiner, B.C. Moy, K.S. Smith, W.G. Tarpley, V.E. Groppi, B.K. Bhuyan
Primary Institution: The Upjohn Company
Hypothesis
Are menogaril-resistant P388 leukemia cells also multidrug resistant?
Conclusion
Menogaril-resistant P388 cells do not exhibit the typical multidrug resistant phenotype and are not cross-resistant to several unrelated drugs.
Supporting Evidence
- P388/MEN cells were 40-fold more resistant to menogaril compared to sensitive P388/0 cells.
- Resistance to menogaril was stable for at least 2 months in the absence of the drug.
- P388/MEN cells did not show significant amplification or overexpression of the mdr gene.
- Uptake and efflux of menogaril were similar in both resistant and sensitive cell lines.
Takeaway
Researchers created leukemia cells that are resistant to a drug called menogaril, and they found that these cells are not resistant to other drugs like some other cancer cells are.
Methodology
P388 cells were exposed to increasing concentrations of menogaril over four months to develop resistance, followed by cloning and various assays to assess drug resistance.
Limitations
The study primarily focuses on one type of leukemia cell line, which may limit the generalizability of the findings.
Want to read the original?
Access the complete publication on the publisher's website